Close menu




December 10th, 2020 | 10:59 CET

AdTiger, Formycon, CureVac - Brilliant to the finish line!

  • Investments
Photo credits: pixabay.com

It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: KYG009701064 , DE000A1EWVY8 , NL0015436031

Table of contents:


    AdTiger - Ingenious Marketing

    AdTiger is an online advertising platform from China. Not well known in Europe so far, the agency deals with advertising contents of advertisers, as well as the diverse interests of the associated publishers. It is about efficient advertising channels, design and content. While Covid-19 spreads more and more across the planet, AdTiger managed to adjust its business model to the additional demand of app developers and educational institutions. The initially expected dent in growth quickly turned into public relevant projects and government contracts in the service of education and information of society.

    Important in this context is good cooperation and the strong presence of AdTiger with social platforms such as Snapchat, Facebook, Twitter or Yahoo. Their growth also brings with it corresponding demand and potential in online business for AdTiger. Since the outbreak of the pandemic, online activities around the globe have grown by an average of 46%. In addition to contact platforms, the demand for online education and training is incomparably more vital than in previous years, at 27%.

    All in all, AdTiger succeeds in transporting the lower circulation of offline media into a higher penetration of its online advertising content. Even if the pandemic should disappear one day, AdTiger has completely taken care of its digitization transfer and uses the changed habits of its clients to increase sales and profits. In pandemic times, ingenious marketing means contactless presence and content excellence. AdTiger currently costs EUR 78 million on the stock exchange and is listed in Frankfurt at EUR 0.13 per share. It is worth taking a closer look here.

    Formycon - Genius Antibodies

    We received another announcement in the area of Covid-19 control yesterday from Munich-based biosimilar expert Formycon. Since today, we know that Formycon is not only working on the biosimilars but also, with the help of Bavarian research funds, on the development of antibodies against the coronavirus. Based on Formycon's clinically validated experience with antibodies and antibody fusion proteins, the Company started the development of an ACE2 antibody fusion protein with the internal code FYB207 in March 2020 - shortly after the outbreak of the Covid-19 pandemic in Europe.

    SARS-CoV-2 and other coronaviruses use ACE2 on the surface of human cells as an entry point for respiratory infections. Formycon has therefore linked the human ACE2 protein to the constant portion of human antibodies using computer-aided structural design, creating a very effective SARS-CoV-2 blocker. Different variants of the virus blocker were investigated on a laboratory scale for producibility, stability and virus inhibition. In vitro tests with isolates of SARS-CoV-2 as well as the original SARS-CoV from 2003 show that Formycon's ACE2 antibody fusion protein effectively binds to SARS coronaviruses and completely prevents infection of the cells. That sounds brilliant!

    Compared to vaccines and therapeutic antibodies, the ACE2 antibody fusion protein is maximally protected against virus evasion by mutation. The risk of infection amplification by vaccines and IgG1 antibodies described for coronaviruses is minimized by using the IgG4 portion in the fusion. FYB207 also has inherent enzymatic activity that may provide additional protection for the lungs and cardiovascular system in symptomatic patients. Furthermore, FYB207 can potentially be used against all coronaviruses that use ACE2 as an entry point.

    Formycon, together with its research partners, is receiving a grant of €290,000 from the Bavarian Research Foundation for this project. The share price went through the roof today with a plus of 75%, bringing the market capitalization to almost EUR 600 million in one go.

    CureVac - Ingeniously placed

    CureVac is a biopharmaceutical Company and has been owned for years by the Hopp family (known through the success story SAP). From the very beginning, the declared goal was to carry out research in precisely those areas which, for various reasons, the highly commercial pharmaceutical companies, in particular, leave out. It is an ironclad goal to take care of things that seem to promise little profit, but in the end, are a useful achievement. Again I am thinking of the cuckoo clock!

    CureVac is a research Company in the field of mRNA technology, an essential part of human protein and immune research. With its expertise, CureVac is working on the development and optimization of the most versatile molecules for medical use. The principle of CureVac's proprietary technology is based on the use of mRNA as an information carrier to guide the body to produce appropriately encoded proteins that can be used to fight a variety of diseases. The Company applies its technologies to the development of prophylactic vaccines, cancer therapies, antibody therapies and protein therapies.

    With approximately 500 employees today, CureVac has been researching difficult issues since 2000 and has not brought to light much of the essential research until early 2020. From 2006 to 2014, CureVac was financed solely by Dievini Hopp BioTech Holding, a biotech venture capital Company owned by Dietmar Hopp. Through this investment, CureVac's capital grew to a total of EUR 145 million. Then came COVID-19 and the Company, which had been burning money for two decades, was floated on the stock exchange at an initial valuation of USD 2.3 billion. The mission is now to produce a viable vaccine against Corona, and if you believe the stock market, the tenfold increase in the price from USD 14 to USD 140 probably carries the one important message: they can do it!

    Regardless of how the story turns out, it was placed 100% ingeniously, because people like Dietmar Hopp are simply ingenious, even if it sometimes takes 20 years before the fruits can be harvested. With a current stock market valuation of EUR 24 billion without product, you will go down in history anyway.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read